Premium Reports
Contact KLAS
 Download Report Brief  Download Full Report    Zoom in charts

Preferences

   Bookmark

Related Series

Oncology 2023
|
2023
Oncology 2020
|
2020
Oncology 2016
|
2016
Oncology 2014
|
2014
Oncology 2013
|
2013
Oncology 2012
|
2012
Oncology IS 2011
|
2011
The Oncology IT Balancing Act
|
2010

Related Segments

 End chart zoom
Oncology 2008 Oncology 2008
* A page refresh may be necessary to see the updated image

Oncology 2008

June 20, 2008

Oncology is a challenging market to compete in. Protocols utilized in medical oncology are more complex than those used in other medical specializations. Tracking mechanisms must be extremely accurate in the ordering and calculations of chemotherapy drugs. Features that are relatively standard in other IT applications, such as scheduling, billing, and changing a patient's treatment plan, become a challenge to successfully implement in an oncology environment.

Overall, the market is fairly immature with only a modest number of vendors currently delivering medical oncology solutions. There are, however, several vendors poised to enter the market. Providers have many questions regarding which vendors are proven to work in oncology, where the big IT vendors are in this market, what viable solutions are available today, and what impacts do these solutions have in helping cancer organizations.

Three vendors who qualified for ranking in the Oncology study were:

  • IMPAC Oncology
  • IntrinsiQ IntelliDose
  • Varian ARIA

The study sample represents an even mix between inpatient and outpatient organizations. Additional vendors are included in the report with anecdotal information.

 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.

Related Segments

​